FDA Finalizes Guidance on ANDA Amendment Review Timeframes

The FDA spells out how long it expects to take to review amendments to generic drug applications in a final guidance that reflects the agency’s commitments under the Generic Drug User Fee Amendments of 2022 (GDUFA III).
Source: Drug Industry Daily